Identifying novel acute pancreatitis sub-phenotypes using total serum calcium trajectories
BMC Gastroenterology · 23.04.2024 · 24 (1)
DOI: 10.1186/s12876-024-03224-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Gastroenterology, online erschienen am 23.04.2024. Verfasst von Chang-Li Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of FSTC Clinic, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003, Hangzhou, China. Hauptthemen laut MEDLINE: Pancreatitis, Calcium, Hospital Mortality, Phenotype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang University "Hundred Talents Program", National Natural Science Foundation of China, Zhejiang University “Hundred Talents Program”.
Abstract (Originalsprache)
Background
Acute pancreatitis (AP) has heterogeneous clinical features, and identifying clinically relevant sub-phenotypes is useful. We aimed to identify novel sub-phenotypes in hospitalized AP patients using longitudinal total serum calcium (TSC) trajectories.
Methods
AP patients had at least two TSC measurements during the first 24 h of hospitalization in the US-based critical care database (Medical Information Mart for Intensive Care-III (MIMIC-III) and MIMIC-IV were included. Group-based trajectory modeling was used to identify calcium trajectory phenotypes, and patient characteristics and treatment outcomes were compared between the phenotypes.
Results
A total of 4518 admissions were included in the analysis. Four TSC trajectory groups were identified: “Very low TSC, slow resolvers” ( n = 65; 1.4% of the cohort); “Moderately low TSC” ( n = 559; 12.4%); “Stable normal-calcium” ( n = 3875; 85.8%); and “Fluctuating high TSC” ( n = 19; 0.4%). The “Very low TSC, slow resolvers” had the lowest initial, maximum, minimum, and mean TSC, and highest SOFA score, creatinine and glucose level. In contrast, the “Stable normal-calcium” had the fewest ICU admission, antibiotic use, intubation and renal replace treatment. In adjusted analysis, significantly higher in-hospital mortality was noted among “Very low TSC, slow resolvers” (odds ratio [OR], 7.2; 95% CI, 3.7 to 14.0), “moderately low TSC” (OR, 5.0; 95% CI, 3.8 to 6.7), and “Fluctuating high TSC” (OR, 5.6; 95% CI, 1.5 to 20.6) compared with the “Stable normal-calcium” group.
Conclusions
We identified four novel sub-phenotypes of patients with AP, with significant variability in clinical outcomes. Not only the absolute TSC levels but also their trajectories were significantly associated with in-hospital mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of FSTC Clinic, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003, Hangzhou, China.
- Emergency and Trauma Center, The First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou 310003, Zhejiang Province, PR China.
- Emergency and Trauma Center, The First Affiliated Hospital, Zhejiang University School of Medicine, #79 Qingchun Road, Hangzhou 310003, Zhejiang Province, PR China. jmhust@zju.edu.cn.
Förderung
- Zhejiang University "Hundred Talents Program"
- National Natural Science Foundation of China
- Zhejiang University “Hundred Talents Program”
Zitieren
APA
Li, C. L., Lin, X. C., & Jiang, M. (2024). Identifying novel acute pancreatitis sub-phenotypes using total serum calcium trajectories. BMC Gastroenterology, 24(1). https://doi.org/10.1186/s12876-024-03224-9
Vancouver
Li CL, Lin XC, Jiang M. Identifying novel acute pancreatitis sub-phenotypes using total serum calcium trajectories. BMC Gastroenterology. 2024;24(1). doi:10.1186/s12876-024-03224-9
BibTeX
@article{Li2024,
author = {Li, Chang-Li and Lin, Xing-Chen and Jiang, Meng},
title = {Identifying novel acute pancreatitis sub-phenotypes using total serum calcium trajectories},
journal = {BMC Gastroenterology},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12876-024-03224-9}
}
EUVIMED